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AbstrAct:
Glioblastoma multiforme (GBM) is a highly invasive and deadly brain tumor. Tumor 
cell invasion makes complete surgical resection impossible and reduces the efficacy 
of other therapies. Genome-wide analyses of mutations, copy-number changes, and 
expression patterns have provided new insights into genetic abnormalities common 
in GBM. We analyzed published data and identified the invasion and motility pathways 
most frequently altered in GBM. These were most notably the focal adhesion and integrin 
signaling, and extracellular matrix interactions pathways. We mapped alterations 
in each of these pathways and found that they included the catalytic PIK3CA and 
regulatory PIK3R1 subunit genes of the class IA PI3K. Knockdown of either of these 
genes separately in GBM cell lines by lentiviral-mediated shRNA expression resulted 
in decreased proliferation, migration, and invasion in all lines tested. FAK activity was 
reduced by knockdown of either PIK3CA or PIK3R1, and MMP2 levels were reduced 
by knockdown of PIK3R1. We conclude that PIK3R1, like PIK3CA, is a potential 
therapeutic target in GBM and that it also influences tumor cell growth and motility.
INtrODUctION
Glioblastoma multiforme is the most common 
primary brain malignancy, with a current median survival 
of approximately 15 months in patients with newly 
diagnosed disease following treatment with surgery, 
chemotherapy and radiotherapy [1]. The invasive nature 
of GBM has been frequently implicated as a key feature 
of GBM’s resistance to therapy [2-5]. Targeting pathways 
involved in the invasive phenotype of the tumor could 
be an important component of successful treatment in 
combination with strategies that more directly target the 
cancer cells. 
The sequencing of 20,661 gene coding regions in 
multiple glioblastoma tumors was a significant milestone 
in understanding the genetic basis of GBM [6]. In this 
analysis, Parsons, et al utilized automated sequencing 
approaches and Illumina SNP arrays to identify mutations 
and copy number changes, respectively, in genes in 22 
glioblastomas [6]. Genes found to harbor alterations in 
at least 2/22 tumors, and which had mutation frequencies 
of >10 mutations per Mb of DNA sequenced, were 
subsequently re-sequenced in an additional 83 tumors 
as validation. This sequencing of 22 GBM exomes, 
along  with  detection  of  genomic  amplifications  and 
homozygous deletions, likely identifies the majority of the 
mutated genes driving tumor formation and progression 
in glioblastoma. 
One challenge has been to identify the genetic 
alterations that occur during tumor development that are 
functionally involved in driving tumor formation and 
progression. Carter et al developed the Cancer-specific 
High-throughput Annotation of Somatic Mutations 
(CHASM) program to systematically identify mutations 
in tumors that are likely to drive the cancer phenotype 
[7]. The CHASM program utilizes 49 predictive features 
to  estimate  the  likelihood  that  a  specific  mutation  in 
question is a driver, rather than a passenger mutation [7]. 
This group applied CHASM to a list of 607 missense 
mutations found by Parsons et al in GBM [6, 7]. The Oncotarget 2011; 2:  833 - 849 834 www.impactjournals.com/oncotarget
result was a stringent list of 24 mutations (8% of the total 
mutation list) that have a much higher probability of being 
functionally involved in GBM pathogenesis, and included 
alterations found in the PTEN, TP53, IDH1, and PIK3CA 
genes, among others.
The mutations of functional consequence in 
GBM are responsible for many aspects of its malignant 
phenotype, including cellular invasion. Glioblastoma 
cells exhibit significantly increased motility and invasive 
potential as compared to many brain tumors of lower 
grade [8, 9]. Tumor cell invasion results in an inability 
to cure the tumor via surgery alone, and invading tumor 
cells are more resistant to apoptosis, radiation and certain 
chemotherapies [5, 8-10]. It is likely that anti-invasion/
motility therapy might render these cells more susceptible 
to apoptosis-based chemotherapeutics.
Glioblastoma cell invasion likely occurs through 
multiple mechanisms, beginning with the degradation 
of surrounding matrix proteins by proteases and 
proteinases in order to create a cavity through which 
a tumor cell can migrate [4, 9, 11]. Invading cells must 
detach from neighboring cells and matrix components 
in order to become motile [9, 11]. Cells can then move 
through healthy brain tissue in a receptor-mediated 
fashion that requires receptor turnover, including the 
formation and degradation of focal adhesions, and 
cytoskeletal rearrangements [9, 12]. Cell attachments, 
along with receptor and focal adhesion turnover and 
cytoskeleton changes, are controlled in part by complex 
interactions between integrins, receptor tyrosine kinases, 
and pathways such as focal adhesion kinase (FAK) and 
phosphatidylinositol 3-kinase (PI3K) signaling [12-16]. 
Several ECM components themselves, including laminin 
and fibronectin, have been shown to be overexpressed in 
tumors, and downregulation of these components reduces 
invasion and migration of glioblastoma cells [17-21]. 
The rate of proliferation of invading tumor cells is often 
significantly  decreased  when  compared  to  cells  in  the 
main tumor mass [8, 9]. Targeting both proliferating and 
migrating cells is likely essential for an effective therapy. 
The PI3K cascade is an important pathway known 
to be involved in proliferation, invasion, and migration 
in cancer [22-24]. Class IA PI3Ks are heterodimers of a 
p85 regulatory subunit and a p110 catalytic subunit [25, 
26].  Three catalytic subunits exist, and are designated 
p110α, p110β, and p110δ. Five class IA PI3K regulatory 
subunits include p85α,  p85β,  p50α,  p55α,  and  p55γ. 
The p85α  regulatory  and  p110α  catalytic  subunits  are 
the most highly expressed and form heterodimers most 
commonly [26]. Upon localization of the heterodimer 
to the plasma membrane via binding of Src homology 
2 (SH2) domains on the regulatory subunit to activated 
receptor tyrosine kinases, the regulatory subunit 
releases its inhibitory control of the catalytic subunit, 
and the catalytic subunit comes in close contact with its 
lipid substrates. The catalytic subunit phosphorylates 
phosphatidylinositol 4,5-bisphosphate (PIP2), converting 
it to phosphatidylinositol 3,4,5-triphosphate (PIP3). PIP3 
can activate several downstream signaling cascades, 
including the Akt and mTOR pathways, which are involved 
in proliferation and cell survival. PTEN activity converts 
PIP3 to PIP2, thus regulating the level of activation of 
these downstream pathways. Constitutive activation of 
the Akt and/or mTOR pathways and loss of function of 
PTEN can each contribute to tumor progression [27, 28].
The  PIK3CA gene, which encodes the class IA 
PI3K catalytic subunit p110α, has been found to harbor 
mutations in several cancers [29-31]. Approximately 80% 
of p110α mutations cluster in “hot spots” in the helical 
(E542K and E545K in exon 9) and kinase (H1047R in 
exon 20) domains, and were considered to be likely 
drivers of cancer formation and/or progression by Parsons 
et al and Carter et al [6, 7, 29]. However, the majority 
of mutations discovered in PIK3CA, regardless of their 
location, have been shown to constitutively activate the 
catalytic activity of p110α [32]. 
The PIK3R1 gene, which encodes the p85α, p55α, 
and p50α class IA PI3K regulatory subunits, was found 
to be mutated in glioblastoma tumors by Parsons et al and 
amplified in GBMs in multiple studies [6, 33]. PIK3R1 is 
also mutated in other human cancers, including colorectal 
cancer, breast cancer, ovarian cancer, and endometrial 
cancer [34-36]. 
In many cases, PIK3R1 mutations are thought to act 
through the catalytic subunit [34, 37, 38]. p85α inhibits 
the activity of the catalytic subunit by binding of its 
N-terminal SH2 domain to the N-terminus of the catalytic 
subunit [39]. Interaction with a regulatory subunit is also 
important for the stability of the catalytic subunit, which 
may degrade more rapidly in an unbound state [25]. A 
significant number of mutations documented in PIK3R1 
are located in the inter-SH2 or N-terminal SH2 domain 
of p85α, which may result in a regulatory subunit that no 
longer inhibits activity, but still maintains stability, of the 
catalytic subunit [40, 41]. Since p85α regulates the class 
IA PI3K catalytic subunit, mutations in PIK3R1 may 
potentially activate invasion.
Our hypothesis for this work is that there are common 
mutations that activate a defined set of pathways that are 
responsible for the invasive properties in glioblastoma 
cells. We performed an in-depth informatics analysis to 
search for invasion and migration-related pathways that 
are enriched with mutations in GBM. With the recent 
availability of a well defined set of mutations responsible 
for GBM, we hope to determine the likely mutational basis 
responsible for at least part of GBM’s invasive phenotype. 
We mapped many of the GBM mutations to pathways 
that may influence the invasive or migratory phenotype 
of this tumor, including focal adhesion signaling, integrin 
signaling, and extracellular component and receptor 
signaling. We show, as have multiple lines of pre-existing 
evidence that the PI3K signaling cascade is involved in Oncotarget 2011; 2:  833 - 849 835 www.impactjournals.com/oncotarget
each of these pathways and is likely to play an important 
role in both the proliferative and migratory/invasive 
phenotypes observed in GBM cells. shRNA-mediated 
knockdown of either the PIK3CA or PIK3R1 gene 
resulted in reduced proliferation, migration, and invasion 
in glioblastoma cell lines, and in the case of the PIK3R1 
gene these effects are independent of the Akt pathway. Our 
studies suggest for the first time that PIK3R1 may play an 
important role in the invasive and migratory capabilities 
of GBM cells, and that the p85α product of this gene may 
be an effective anti-invasion target.
rEsULts
Invasion and migration-related pathways are 
mutated in GbM
Using GBM sequencing and genomic copy number 
data,  we  sought  statistically  significant  invasion  and 
motility-related pathways enriched for genes mutated 
in GBM. A similar analysis was performed using gene 
expression data from the same tumors sequenced for 
mutation.
Our analyses included a comprehensive list of 703 
genes mutated in GBM (Table S2), and a smaller more 
stringent list of 59 high probability driver mutations (Table 
S3) developed from the combined findings of Parsons et al 
[6], Carter et al [7], and Rao et al [33]. Transcript counts 
produced by next generation sequencing, a variation 
of Serial Analysis of Gene Expression (SAGE), were 
analyzed from Parsons et al [6]. This gene expression 
data covered 20,619 curated genes in 16 human tumors. 
Mutation data was analyzed using Ingenuity Pathway 
Analysis and Partek Genomics Suite, while SAGE 
data  was  studied  using  Spotfire  DecisionSite.  The  use 
of Partek and Ingenuity simultaneously increases the 
validity and significance of our analysis, given that these 
programs produce results based upon algorithms that are 
complementary, but do not overlap.
Using the expanded and stringent mutated gene 
lists, we searched for enriched ontologies, based upon 
molecular function, cellular component, and biological 
process  as  defined  by  the  Gene  Ontology  Consortium, 
using Partek Genomics Suite. Additionaly, we searched 
for enriched canonical pathways using Ingenuity Pathway 
Analysis, which ranks genes based on their function rather 
than inclusion within an ontological group. Both programs 
generated lists of pathways altered in GBM, each of which 
was assigned statistical significance (p-value greater than 
or equal to 0.5) (Tables S4-S7). We found that many of the 
statistically significant frequently mutated pathways were 
involved directly in the invasive or migrational phenotype 
in GBM (Tables S8, S9). Within these pathways, we also 
analyzed SAGE expression data to determine the presence 
of genes up- or down-regulated by 5-fold or greater. We 
mapped alterations in several of these enriched pathways, 
including focal adhesion signaling (Fig. S1), integrin 
signaling (Fig. S2), and extracellular matrix interactions 
(Fig. S3).
class IA PI3K plays a role in most invasion and 
migration-related pathways in GbM
In studying the genes involved in the mutation-
enriched invasion and migration-related pathways, we 
found that the class IA PI3K subunit genes PIK3CA and 
PIK3R1 were central signal transducers in essentially all of 
the pathways studied (Fig. 1, S1, S2). PIK3CA is mutated 
in approximately 10% of GBMs and, PIK3R1 is mutated 
in approximately 8% [29, 31, 35, 42]. The role of PIK3CA 
in tumor cell proliferation is well-studied as compared to 
its role in invasion. Examination of the original gene list 
(703 mutated genes) and the stringent gene list (59 likely 
driver mutations) produced results that were typically 
in agreement (Tables S4-S9). Results (p-values) will be 
discussed in terms of the stringent gene list analysis, due 
to the higher likelihood that these mutations are drivers of 
GBM formation. When this list was analyzed in Ingenuity 
Pathway Analysis, PIK3CA and PIK3R1 were found 
to be involved in several important motility pathways, 
including focal adhesion (p<0.0001), integrin (p = 
0.0004), Rac (p = 0.0046), and axonal guidance signaling 
(p = 0.0065). Similarly, when this list was analyzed in 
Partek Genomics Suite, both subunits were found to be 
involved in regulation of cell adhesion (p<0.0001), cell 
motion (p<0.0001), focal adhesion formation (p<0.0001), 
and the integrin-mediated signaling pathway (p = 0.0019). 
The results of analyses in Partek and Ingenuity, which use 
complementary algorithms but do not overlap, were in 
agreement in terms of the significance of the invasion and 
migration-related pathways that are mutated/aberrantly 
expressed in GBM, and in the involvement of PIK3CA 
and PIK3R1 in these pathways. The PI3K cascade itself 
was found to be statistically significantly altered in GBM 
by both the Ingenuity (p<0.0001) and Partek programs 
(p<0.0001).
the sKMG26, Hct116, and 081024 cell lines 
harbor PIK3CA mutations
In determining the mutational status of the PIK3CA 
gene in our cell lines, we sequenced the 10 most commonly 
mutated exons (1, 2, 4, 5, 7, 9, 12, 13, 18, 20) [6, 29, 31]. 
One glioblastoma line, SKMG26, and one colorectal cancer 
line, HCT116, have been previously sequenced. SKMG26 
and HCT116 lines each bear a single somatic mutation 
in the kinase domain of the catalytic subunit (exon 20) 
[29, 31]. These mutations induce H1047Y and H1047R 
amino acid changes, respectively [29, 31]. In SKMG26 Oncotarget 2011; 2:  833 - 849 836 www.impactjournals.com/oncotarget
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Figure 1: the PI3K pathway is central to proliferation, migration, and invasion in GbM cells. Upon activation at the 
plasma membrane, the catalytic subunit of class IA PI3Ks phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2), converting it to 
phosphatidylinositol 3,4,5-triphosphate (PIP3). This results in the activation of several downstream pathways, including the Akt and mTOR 
pathways, which leads to increased proliferation and survival. PTEN activity converts PIP3 to PIP2. Interestingly, the p85α regulatory 
subunit has been shown to bind PTEN directly and enhance its lipid phosphatase activity [62]. This subunit may also be involved in the 
activation of migration and invasion-promoting pathways, possibly through the activation of small GTPases such as Cdc42 and Rac [23, 
63]. p85α may interact with caspase 8 (in a non-apoptotic function of this caspase) to increase cell motility and Rac activation [55]. p85α 
has also been shown to interact with FAK, and this interaction correlates with FAK activation [14]. Oncotarget 2011; 2:  833 - 849 837 www.impactjournals.com/oncotarget
cells, this constitutes a change from a hydrophilic to an 
intermediate side chain at amino acid 1047. In HCT116 
cells, amino acid 1047 remains hydrophilic. We confirmed 
the presence of these mutations in both cell lines (data 
not shown). Previous work by Samuels et al found that 
knockdown of the wild-type PIK3CA allele in HCT116 
lines increased proliferation and invasion in this cell line 
as compared to the parental line under the condition of 
serum starvation [22]. Similarly, removal of the mutant 
allele resulted in significantly decreased proliferation and 
invasion under the same conditions. These effects were 
apparent under normal serum conditions, but were not as 
significant. We obtained the mutant allele only (HPIK3CA 
MT #125) and wild-type allele only (HPIK3CA WT #123) 
lines from Dr. Bert Vogelstein (Johns Hopkins), to be 
applied as a comparison for our own studies.
Two glioblastoma stem-like neurosphere lines, 
without genome wide sequencing data, were produced in 
our laboratory from patient tumors, 081024 and 081110. 
These and the D54 glioblastoma line were sequenced for 
PIK3CA mutations using published primer sequences 
(Table S1) [6]. While 081110 was devoid of mutations 
in this subunit, 081024 carried 3 mutations on exon 13, 
each of which has been documented as a SNP (NCBI 
dbSNP database) [43]. These mutations represented the 
following amino acid substitutions: V680L, E707K, and 
L719V. Two of these SNPs (V680L and L719V) were 
present in D54 cells. None of these substitutions changes 
the hydropathicity of the residue, and no other mutations 
were noted.
PIK3CA knockdown decreases Akt activation in 
GbM cell lines, and knockdown of either PIK3CA 
or PIK3R1 reduces FAK activity
To study the effects of PIK3CA and PIK3R1 
abrogation in GBM, we significantly reduced protein levels 
of p110α and p85α using a lentiviral expression vector 
containing shRNAs targeting each mRNA independently. 
We knocked-down expression of each subunit separately 
(and in combination) in the SKMG26, D54, HCT116, 
081024, and 081110 cell lines. We produced controls 
for each line containing only an empty lentiviral vector 
and no shRNA. Knockdown was confirmed by western 
blot (Fig. 2A). Although interaction between the PIK3R1 
and  PIK3CA gene products may be important in the 
stabilization of the catalytic subunit, we did not observe 
much decrease in p110α protein levels upon knockdown 
of p85α.
Figure 2: Confirmation of PIK3CA and PIK3R1 knockdown in cell lines. A, PIK3CA and PIK3R1 class IA PI3K subunit 
expression was reduced using lentiviral-mediated shRNA targeted to each subunit specifically, and to each in combination. B, FAK 
activation at Y397 was observed for each cell line. C, Akt activation at T308 and S473 was observed, as was PTEN status. 
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Figure 3: PIK3CA or PIK3R1 knockdown reduces proliferation of various cancer cell lines. Cells were plated at 500 or 
1000 cells/well and proliferation was measured once per day using the Cell Counting Kit-8 reagent. At 144 hours, all PIK3CA and PIK3R1 
knockdown cell lines showed significantly reduced levels of growth as compared to parental and control lines. A more pronounced decrease 
in proliferation was noted in SKMG26 cells as a result of knockdown of both PIK3CA and PIK3R1. * represents a p-value ≤ 0.05, and 
compares a given result to that of the parental line. 
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Figure 4: colony formation is reduced on plastic and soft agar due to either PIK3CA or PIK3R1 knockdown. A, Cells 
were plated on treated plastic 6-well plates at 100, 250, and 500 cells/well. Colonies were stained and counted at ~2 weeks post-plating. 
In all cells, PIK3CA or PIK3R1 knockdown resulted in a decrease in colony number. B, Cells were plated at 100 and 250 cells/well in top 
plugs containing appropriate media and 0.4% agarose. At ~2 weeks post-plating, colonies were stained, measured, and counted. A colony 
was counted as positive if it matched or exceeded the average size of colonies formed by the parental line. In all cell lines, PIK3CA or 
PIK3R1 knockdown reduced both colony size and number of positive colonies. * represents a p-value ≤ 0.05, and compares a given result 
to that of the parental line. Oncotarget 2011; 2:  833 - 849 840 www.impactjournals.com/oncotarget
We examined the phosphorylation levels of Akt 
at Ser473 and Thr308 in HCT116, D54, and SKMG26 
cell  lines.  Akt  activation  was  significantly  reduced  at 
both residues in cells following PIK3CA knockdown 
(Fig.2C). In HCT116 lines, this is similar to the decrease 
in Akt activity seen in HPIK3CA WT #123 lines, which 
contain only the wild-type PIK3CA allele. PIK3R1 
knockdown did not result in reduced Akt activation, and 
in the case of SKMG26, this seemed to increase levels 
of phosphorylation at both of the above residues. In the 
081110 neurosphere line, Akt activity was slightly reduced 
by both PIK3CA and PIK3R1 knockdown. PIK3R1 and 
PIK3CA knockdown in 081024 neurospheres resulted in 
a decreased level of Akt phosphorylation at both residues, 
which was more pronounced in the PIK3CA knockdown 
as compared to the PIK3R1 knockdown. Neither 
neurosphere line showed decreased Akt phosphorylation 
at levels as significant as in the three adherent lines. These 
results differentiates the 3 adherent lines from the 2 non-
adherent neurosphere lines, suggesting that PIK3CA 
knockdown may not affect Akt activity as significantly in 
neurospheres as compared to adherent lines. 
We also studied the activity of FAK (PTK2) in all 
lines at the Y397 residue (Fig.2B). Both PIK3R1 and 
PIK3CA knockdown significantly decreased FAK activity 
in all lines tested.
Knockdown of PIK3CA or PIK3R1 reduces 
proliferation in GbM cells in vitro, regardless of 
PIK3CA mutational status 
Abrogation of either the PIK3CA or PIK3R1 genes 
significantly reduced proliferation at 144 hours in all 5 
cell lines (Fig. 3). Interestingly, in SKMG26 and D54 
lines,  PIK3R1 knockdown resulted in a more reduced 
proliferation rate than did PIK3CA knockdown. The 
combined knockdown of PIK3CA and PIK3R1 only 
showed a greater effect than either knockdown alone in 
SKMG26 lines.Similarly, in SKMG26, D54, and HCT116 
the colony formation capabilities of the PIK3CA and 
PIK3R1 knockdown lines were reduced both on treated 
plastic and, more significantly, in soft agar (Fig. 4). In D54 
and SKMG26 lines, both PIK3CA and PIK3R1 knockdown 
lines  showed  significantly  reduced  colony  numbers  on 
plastic as compared to parental lines and controls, with the 
greatest reduction due to PIK3R1 abrogation (p<0.0001). 
In HCT116 cells, PIK3CA knockdown resulted in a 
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Figure 5: Neurosphere size and number is reduced in PIK3CA and PIK3R1 knockdown cell lines. Cells were plated at 1, 5, 
10, 100, 250, and 500 cells/well, and at ~2 weeks post-plating, neurospheres were counted and measured. A sphere was considered positive 
if it matched or exceeded the average size of spheres formed by parental lines. In both 081110 and 081024 cell lines, PIK3CA and PIK3R1 
knockdown resulted in reduced neurosphere size and number of positive spheres per well. * represents a p-value ≤ 0.05, and compares a 
given result to that of the parental line. Oncotarget 2011; 2:  833 - 849 841 www.impactjournals.com/oncotarget
more reduced colony number than PIK3R1 knockdown, 
although this was not statistically significant. 
In soft agar, a colony was counted as positive if it 
matched or exceeded the average size of colonies formed 
by the parental line. SKMG26 cells did not form colonies 
in soft agar at any agar concentration or cell number. 
In D54 cells, PIK3R1 knockdown resulted in a greater 
reduction in colony size and number of positive colonies 
than  PIK3CA knockdown, while PIK3CA knockdown 
showed a slightly greater effect in HCT116 cells. 
HPIK3CA WT #123 cells also exhibited reduced colony 
size and number, although this was not as significant as 
that seen in knockdown lines. HPIK3CA MT #125 cells 
showed an increase in colony size and number, although 
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Figure 6: PIK3CA knockdown results in reduced cell migration rates on fibronectin and laminin, and both PIK3CA 
and PIK3R1 knockdown reduce invasion through Matrigel. A, Cells were plated on fibronectin or laminin and were imaged 
every 5 minutes for 24 hours. Average velocity and distance traveled were measured at 6, 8, 12, 16, and 24 hours, and trends were similar 
for each time point (graph represents the 16 hour time point). In both D54 and SKMG26 cells, PIK3CA knockdown did not result in a 
statistically significant reduced migration rate on fibronectin. PIK3R1 knockdown reduced migration rates in both lines. D54 lines did not 
adhere to laminin-coated surfaces. In SKMG26 lines on laminin, both PIK3CA and PIK3R1 knockdown significantly reduced the average 
rate of cell migration, with the combined knockdown resulting in the greatest decrease in velocity. * represents a p-value ≤ 0.05, and 
compares a given result to that of the parental line. B, Cells were plated at 2.5x105 or 5x105 cells/well on BD Biocoat Matrigel Invasion 
Assay inserts. At 24 or 72 hours, migrated (control) and invaded (experimental) cells were stained and counted. Percent invasion is provided 
for each cell line. Both PIK3CA and PIK3R1 knockdown resulted in a reduced percent invasion as compared to parental lines and controls. 
* represents a p-value ≤ 0.05, and compares a given result to that of the parental line. Oncotarget 2011; 2:  833 - 849 842 www.impactjournals.com/oncotarget
this was not statistically significant.
081024 and 081110 PIK3CA and PIK3R1 
knockdown  lines  formed  significantly  smaller  colonies 
over 2 weeks than parental and control lines (Fig. 
5). These data suggest that cells lacking PIK3CA or 
PIK3R1 experience significantly reduced survival under 
anchorage-independent conditions. 
Knockdown of PIK3CA or PIK3R1 reduces GbM 
cell invasion and migration on laminin and 
fibronectin
Fibronectin and laminin are two components of 
brain extracellular matrix that have been found to be 
upregulated in glioblastoma, and both may play a role in 
tumor migration and invasion [17, 19]. Evidence suggests 
that differential interaction with matrix components 
may affect the migrational and proliferative capabilities 
of tumor cell lines. Sengupta et al found that shRNA-
mediated  inhibition  of  fibronectin  expression  delayed 
GBM tumor progression in mice [21]. Nagato et al 
showed  that  knockdown  of  laminin  α4  chain  severely 
limited tumor invasion in vivo [20].
Cells  were  plated  on  fibronectin  or  laminin  and 
were imaged using an Olympus IX81 microsope for 24 
hours in order to study the migrational capabilities of the 
knockdown cell lines. As HCT116 cell lines tend to divide 
quickly and grow in clumps, migration studies focused 
on the D54 and SKMG26 lines, which are more motile 
and therefore trackable. Cells were tracked individually 
using the Manual Tracking program in ImageJ [44, 45]. 
081110 and 081024 lines were not tested in this capacity, 
as  they  did  not  adhere  to  laminin  or  fibronectin.  On 
fibronectin,  PIK3CA knockdown resulted in a reduced 
average velocity (µm/min) and distance traveled (µm) in 
both SKMG26 and D54 cell lines as measured at 6, 8, 12, 
16, and 24 hours, although not in a statistically significant 
manner (Fig. 6A, Videos S1-S3). PIK3R1 knockdown 
did significantly lower velocity and distance traveled in 
both cell lines (Videos S4-5). In SKMG26 cells (but not 
in D54 cells), combined PIK3CA and PIK3R1 knockdown 
resulted in the greatest decrease in overall velocity (Video 
S6). D54 cells did not adhere to laminin-coated surfaces. 
SKMG26 cells on laminin showed significantly reduced 
migration rates after knockdown of either the PIK3CA 
or  PIK3R1 subunit (Fig. 6A). Migration velocity was 
decreased more drastically due to PIK3R1 than PIK3CA 
knockdown, and no combinatorial effect was observed 
due to combined knockdown. Overall, migration velocity 
was more greatly reduced on laminin as compared to 
cells observed on fibronectin. Cell migration rates were 
reduced in the PIK3R1 knockdown line as compared to 
A B
Figure 7: Protease activity is altered in PIK3R1 knock down cell lines. The 48 hour conditioned medium of adherent or 
suspension cell lines was collected and subjected to gelatin or casein-plasminogen zymography. PIK3R1 knock down resulted in reduced 
MMP-2 and uPA activity in neurosphere lines. MMP-9 was reduced in all knock downs in D54 cells. Knock down or mutation of PIK3CA 
resulted in decreased uPA in HTC116 cells.Oncotarget 2011; 2:  833 - 849 843 www.impactjournals.com/oncotarget
the parental SKMG26 line by 68.0% on laminin versus 
38.8% on fibronectin at 16 hours.
We used the BD Biocoat Matrigel Invasion Assay 
to test the invasive capabilities of SKMG26, D54, and 
HCT116 cells lacking PIK3CA or PIK3R1 mRNA. For all 3 
lines, both PIK3R1 and PIK3CA knockdown significantly 
reduced the number of invaded cells versus controls, 
with the lowest percent invasion in PIK3CA knockdown 
lines (Fig. 6B). Together, these data suggest that PIK3R1 
plays an important role in the rate of migration, while 
PIK3CA loss may lead to a greater reduction in invasive 
capabilities. Both of these characteristics are likely to be 
important in the infiltration of healthy non-tumor brain 
tissue by GBM cells.
MMPs and uPA are reduced as a result of 
knockdown
Gelatin and casein plasminogen zymograms showed 
that treatment with PIK3R1 shRNA resulted in a decrease 
in MMP2 and uPA activity in both 081024 and 081110 
neurosphere lines (Figure 7). PIK3CA knockdown caused 
no change in activity. In D54 lines, MMP2 activity was 
similarly reduced by PIK3R1 knockdown, but not by 
PIK3CA knockdown. D54 cells also express MMP9, 
which was reduced in all knockdowns as compared to 
control lines.
DIscUssION
Invasion and migration-related pathways were 
among  the  most  statistically  significantly  enriched  for 
mutations and expression alterations in our informatics 
studies using Ingenuity, Partek, and Spotfire. Central to 
many of these pathways is PI3-Kinase signaling. The 
validity of our results is strengthened by the similarly 
significant presence of pathways involved in cell cycle 
control, apoptosis, and proliferation (Tables S4-S7). 
Much research has focused on elucidating the 
mechanisms of tumor formation and progression caused 
by individual common mutations, such as PTEN and p53 
loss of function, EGFR amplification, or the EGFRvIII 
variant. However, considering the pathways that are 
enriched for aberrations may give a more comprehensive 
view of tumor function. Although we have not addressed 
epigenetic mechanisms in this study, these should not be 
excluded from further considerations of the underlying 
mechanisms for promoting invasion. 
Our informatics studies focused primarily on 
pathways that may affect motility in GBM cells. We 
found that focal adhesion signaling, integrin signaling, 
and extracellular component and receptor signaling 
commonly contained clusters of mutations and/or 
aberrantly expressed genes (Fig. S1-S3). These signaling 
pathways are highly interconnected, and most certainly 
experience altered communication in tumors. While 
many of the mutations found may be passengers, and thus 
may not support tumor growth or motility, some, such as 
mutations found in receptor tyrosine kinases, have already 
been shown to play a role in cancer [46].
Several integrins are upregulated in GBM, 
and knockdown of these proteins results in reduced 
migration and invasion [47, 48]. Our studies confirmed 
the upregulation of a collection of integrin subunits 
as compared to normal brain samples by over 5-fold, 
including αv (8.6-fold), α2 (8.6-fold), α4 (36.9-fold), and 
β8  (8.3-fold).  Several  other  subunits  were  upregulated 
at  lower  levels,  including  β3  (3.6-fold).  Each  of  these 
subunits was expressed in at least half of the tumors 
studied. The α4 subunit was also found to bear a mutation. 
Matsunaga et al. showed that knockdown of VLA-4 in 
acute myelogenous leukemia cells resulted in increased 
susceptibility of to anoikis- or drug-induced apoptosis 
[49]. This was likely caused by a reduction in PI3K 
activity, which is activated by the interaction of the α4 
integrin subunit of VLA-4 and fibronectin. Treatment of 
mice by the same group with an anti-VLA-4 antibody 
resulted in 100% survival at 62 days. 
At least partially dependent on integrin signaling, 
focal adhesion turnover is likely to be highly important in 
the migration of tumor cells through healthy brain tissue 
[12, 14]. The FAK protein itself was neither mutated nor 
dysregulated according to our studies, although it has been 
shown to be upregulated in a subset of breast tumors [50]. 
However, several proteins that may influence the activity 
of this pathway were upregulated and/or mutated in GBM 
by  our  findings.  This  includes  the  integrins  discussed 
above, several of which, such as the β3 subunit, activate 
FAK signaling. Similarly, activated EGFR and PDGFRA, 
both of which are upregulated (61.7- and 6.8-fold, 
respectively) and mutated in GBM, can aid in the activation 
of the FAK pathway [51]. PI3K, PTEN, RAP1B, TLN1, 
SOS, MAP3K11, TTN, BCAR3, and ROCK1 were each 
mutated in GBM in our studies, and ROCK1 was found to 
be upregulated by 8.4-fold as compared to normal brain. 
NRAS, ARPC1B (subunit 1B of the Arp2/3 complex), 
PDGFC, PDGFD were upregulated by 13.7-, 5.4-, 16.3-
, and 5.5-fold respectively. Interestingly, Fotiadou et al 
found that mouse embryonic fibroblasts lacking NRAS 
also lacked phosphorylated FAK, and knockdown of 
NRAS may be useful in reducing migration in tumors[52].
Extracellular matrix components and their cell 
receptors play an important role in both integrin signaling 
and FAK signaling as discussed above. Many structural 
matrix components are overexpressed or mutated in 
GBM, and tumor cells may in fact express components 
that can increase their migratory capabilities [17, 19]. The 
fibronectin 1 (FN1) gene carried a mutation in 1 tumor, 
and the COL3A1 gene was considered a potential driver by 
Parsons et al. , with 3 mutations in individual tumors [6]. 
Several other collagen genes were mutated (COL14A1, Oncotarget 2011; 2:  833 - 849 844 www.impactjournals.com/oncotarget
COL23A1, COL4A2, COL4A2, COL4A5, COL6A3, and 
COL6A6 , and COL3A2 was found to amplified by Rao 
et al [33]. FN1, 2 laminin genes (LAMC1, LAMA4), and 
a collection of collagen genes (COL1A1,  COL20A1, 
COL5A1,  COL4A2,  COL1A2,  COL12A1,  COL22A1, 
COL6A1, COL28A1, COL6A3) were upregulated in tumors 
as compared to normal brain. Several additional collagen 
genes were overexpressed, but were not expressed in at 
least half of the tumors studied.
Given that rapid cell proliferation is inherent 
in GBM and is responsible for the production of the 
main tumor mass, the roles played by PI3K signaling 
in proliferation and tumor growth are most commonly 
studied in GBM. However, our results show that the 
PIK3CA gene, encoding the class IA PI3K catalytic 
subunit p100α, and the PIK3R1 gene, encoding the p85α, 
p55α,  and  p50α  regulatory  subunits,  may  also  be  key 
components of the migratory/invasive phenotype in these 
tumors. Interestingly, while knockdown of either of these 
subunits reduced proliferation, migration, and invasion 
in all cell lines tested, the extent of these effects differed 
slightly in each line. A measurably greater effect resulting 
from combined PIK3CA and PIK3R1 knockdown, as 
compared to knockdown of a single gene alone, was 
observed only in SKMG26 cells. Our studies show that 
the effects caused by abrogation of PIK3R1 and PIK3CA 
result from different signaling mechanisms in individual 
cell lines, likely reflecting different signaling mechanisms 
in the individual tumors (and perhaps in individual cells 
of the same tumor). . Although signaling responses to 
PIK3CA and PIK3R1 knockdown differ among cell lines, 
proliferation, migration, and invasion were decreased in 
all lines tested. 
p85α activity in the invasive/migratory phenotype 
has yet to be fully elucidated. p85α may, at least in part, 
act through focal adhesion signaling, as knockdown 
results in decreased FAK activation. Cells treated with 
PIK3R1-targeting shRNA show a more reduced average 
velocity than cells treated with PIK3CA-targeting shRNA. 
However, these cells are still motile on both fibronectin 
and laminin, and thus the FAK signaling pathway is 
likely only one component of GBM cell motility. Notably, 
while both PIK3CA and PIK3R1 knockdown significantly 
reduces FAK activity in D54 glioblastoma cells, only 
reduction in PIK3R1 expression results in statistically 
significantly  slowed  cell  migration,  supporting  the 
only partial role played by FAK signaling in GBM cell 
motility. The p85α protein product of PIK3R1 has been 
shown to interact with several small GTPases, including 
Cdc42, Rac, and Rho, that through various mechanisms 
increase cell motility [23, 53]. Park et al found that 
mir-29 microRNAs upregulate p53 levels, and induce 
apoptosis, potentially by direct suppression of PIK3R1 
and CDC42 [54]. p85α may also interact with caspase-8 to 
stimulate motility through Rac activation [55]. Similarly, 
PIK3R1 knockdown reduced MMP2 and uPA levels in 
neurospheres, and reduced MMP2 and MMP9 levels in 
D54 cells, and reduction of the levels of these proteins 
has been shown to cause reduced migratory and invasive 
capacity in glioblastoma cells [56, 57]. 
There are a variety of small molecule inhibitors 
available  that  target  p110α,  albeit  non-specifically, 
including LY294002 and wortmannin. These and other 
PI3K inhibitors have been shown to reduce angiogenesis, 
induce radiosensitivity, and reduce proliferation in GBM 
cells [58-61]. Although PIK3R1 has not been studied 
previously in the context of GBM invasion, given its 
role in the PI3K pathway, and the 2008 discovery of 
its mutation in GBM, it is not surprising that PIK3R1 
knockdown shows evidence of decreased invasion in vitro 
[6]. However, there is currently no inhibitor targeting 
p85α. Based on the concept that a reduction in migration 
may sensitize tumor cells to apoptosis, the development 
of p85α inhibitors used in combination with apoptosis-
inducing chemotherapies may be effective in treatment of 
patients with GBM.
Although much of what has been shown in this 
study has been implicated previously in other cancers, our 
findings support the hypotheses that the PI3K signaling 
pathway  has  the  most  significantly  mutated  genes 
driving cellular invasion. Within the common mutations 
that promote GBM formation and growth, those within 
members of this pathway (PTEN, p110α, p85α and likely 
receptor tyrosine kinases such as EGFR) are initiating 
points for signaling enhanced invasion.. Considering 
the frequency of mutations in the PI3K pathway and its 
role in growth and invasion, it would be reasonable to 
increase efforts to develop molecular therapies targeting 
its pathological signaling in GBM.
MAtErIALs AND MEtHODs
Data collection and Generation of Gene Lists
This study focused on the results of a whole-
genome sequencing analysis of Glioblastoma tumors by 
Parsons et al [6]. We analyzed genes found to be mutated 
via  sequencing,  along  with  ‘target’  genes  identified  as 
amplified or deleted by Illumina SNP arrays. We included 
mutated GBM genes found to be likely drivers of tumor 
formation and progression by Carter et al [7]. This analysis 
also included genes amplified or deleted in more than 2% 
of cases based on a combination of digital karyotyping 
and a review of published studies by Rao et al [33]. In 
total, 703 genes were found to be altered in GBM via 
these data sources.
Since it was likely that many of the low frequency 
mutations were passengers, a more stringent gene list 
was also created that included mutations with higher 
probabilities of being drivers in the formation and invasion Oncotarget 2011; 2:  833 - 849 845 www.impactjournals.com/oncotarget
of GBM. This list included ‘target’ genes identified as 
amplified or deleted by Parsons et al [6], CAN genes from 
the same group that had a passenger probability (low) 
p-value of 0.05 or better, genes found by Rao et al [33] 
with a 4% or greater occurrence, and genes determined 
by Carter et al [7] to be likely drivers via their CHASM 
program. This stringent list included a total of 59 genes 
and was analyzed separately from the full list of 703 genes.
Informatics Analysis of Mutated Gene Lists
Our objective in this analysis was to identify genes, 
functions, or pathways that are involved in the invasive 
tumor phenotype and are enriched in GBM. To identify 
these invasion-related components, we analyzed our lists 
of GBM-specific mutated, deleted, and/or amplified genes 
using the Ingenuity Program (Ingenuity Systems) and 
the Partek Genomics Suite Program (Partek Inc.). The 
Partek Genomics Suite Gene Ontology function allows 
for the analysis of gene ontologies (based upon molecular 
function, cellular component, and biological process 
as defined by the Gene Ontology Consortium) enriched 
in GBM tumors. Based on a gene list, Partek assigns 
statistical  significance  to  each  function,  component, 
and process ontology enriched within the list. Statistical 
significance in this program is defined by an ‘Enrichment 
Score,’ which is the negative loge transformation of the 
p-value for the particular ontology. Enrichment Scores 
above 3 (p ≤ 0.05) are considered statistically significant. 
The Ingenuity program analyzes genes based upon gene 
function (as opposed to inclusion in an ontology) and 
organizes results by p-value into statistically significant 
canonical pathways and networks. We analyzed the 
original gene list (703 genes) and the stringent gene list 
(59 genes) separately using both of these programs. 
Additionally,  within  the  identified  statistically 
significant  mutation-enriched  pathways,  the  Spotfire 
DecisionSite program (TIBCO Software Inc.) was 
utilized to identify up- or down-regulated genes based 
on expression data from Parsons et al [6]. This gene 
expression data included 20,619 curated genes in 16 
human glioblastoma tumors.
cell lines
081110 and 081024 non-adherent neurosphere 
lines were produced in our laboratory from human tumor 
samples received immediately following resection from 
consented GBM patients. Neurospheres were cultured in 
NeuroCult NS-A basal medium (StemCell Technologies, 
Vancouver, BC, Canada) supplemented with 10ng/mL FGF 
(PeproTech, Rocky Hill, NJ), 10ng/mL EGF (PeproTech), 
and 0.0004% heparin (StemCell Technologies). HCT116 
cells and HCT116 lines containing only the wild-type 
(HPIK3CA WT #123) or mutant (HPIK3CA MT #125) 
PIK3CA alleles were obtained from Dr. Bert Vogelstein 
(Johns Hopkins), and were grown in McCoy’s Modified 
5A medium (Sigma-Aldrich) supplemented with 10% 
FBS. D54 and SKMG26 cells were grown in DMEM 
(Sigma-Aldrich) supplemented with 10% FBS. 
Lentivirus production
shRNAs targeting the PIK3CA and PIK3R1 mRNAs 
cloned into the vector pLKO.1 and packaged into E.coli 
were obtained from the Expression Arrest-TRC shRNA 
Libraries (Broad Institute of MIT and Harvard). The 
plasmid was amplified on ampicillin-treated plates and 
colonies were then incubated in 6mL LB Broth (Invitrogen) 
overnight at 37°C and 300 RPM. The plasmid was 
purified using the QIAprep Spin Miniprep Kit (Qiagen) as 
described by the manufacturer. 293T cells in 10cm dishes 
were treated with Lipofectamine 2000 (Invitrogen), 
envelope plasmid pMD2.G, packaging plasmid pCMV-
R8.74psPAX2, and hairpin-pLKO.1 plasmid. At 18 hours 
post treatment, the cells were washed and fresh high-
BSA media was added. Lentivirus-containing media was 
collected at 24 and 48 hours and was stored at -80°C until 
used. Lentivirus was also produced that contained only 
the empty pLKO.1 plasmid (no shRNA).
HCT116, D54, SKMG26, 081110, and 081024 cell 
lines were treated with lentivirus targeting either PIK3CA 
or  PIK3R1 plus 8ug/mL polybrene (Sigma-Aldrich). 
Lines were treated in parallel with a combination of both 
PIK3CA and PIK3R1 lentiviruses, and with lentivirus 
containing only the empty pLKO.1 plasmid (no shRNA) 
as a control. At 24 hours, cells were washed, and shRNA-
expressing cells were selected with a concentration of 
puromycin (Invitrogen) ranging from 0.5-2ug/mL for 72 
hours. Cells were then maintained without selection. 
sequencing
Sequencing was performed as previously described 
[29]. Briefly, genomic DNA was purified from cell pellets 
using the DNeasy Blood and Tissue kit (Qiagen). Exons 
1, 2, 4, 5, 7, 9, 12, 13, 18, and 20 were amplified using 
PCR (primers listed in Table S1). PCR products were run 
on 2% agarose gels, and bands were extracted using the 
QIAQuick  Gel  Extraction  Kit  (Qiagen).  Samples  were 
sequenced by GeneWiz (South Plainfield, NJ). 
Growth curves
Cells were treated with 2ug/mL propidium iodide 
(Sigma-Aldrich) and were sorted by a MoFlo cell sorter 
(Dako Cytomation) into 96-well plates at 500, 1000 and 
2000 cells/well. For 7 days post plating, live cells were 
counted daily in 10 replicates per line per day using the Cell Oncotarget 2011; 2:  833 - 849 846 www.impactjournals.com/oncotarget
Counting Kit–8 reagent (Enzo Life Sciences). Absorbance 
was read at 450 nm for 1 second. Results were normalized 
to wells containing media only (no cells).
colony formation assay
Cell were plated in triplicate at 100, 250, and 500 
cells/well in 6-well plates in appropriate medium with 
10% FBS. At two weeks post-plating, colonies were 
stained with crystal violet (Sigma-Aldrich) and counted 
under a light microscope.
colony formation in soft agar
Cells were plated in triplicate at 100 and 250 cells/
well in top plugs containing appropriate media plus 0.4% 
SeaPlaque agarose (Lonza). Bottom plugs contained 
media plus 0.8% agarose. At approximately two weeks 
post-plating, colonies were counted and measured under 
a light microscope.
Neurosphere formation assay
Cells were treated with 2ug/mL propidium iodide 
and live cells only were sorted using a MoFlo cell sorter 
(Cytomation) into 96-well plates at 1, 5, 10, 100, 250, and 
500 cells/well. At two weeks post plating, neurospheres 
were measured for average size and the number of positive 
neurospheres was recorded at each cell concentration. 
Neurospheres were considered positive if they matched 
or exceeded a measurement close to the average size of 
neurospheres formed by the parental cell line. 
In vitro invasion assay
The BD Biocoat Matrigel Invasion Assay was 
performed as described by the manufacturer (Becton 
Dickson). Matrigel inserts were rehydrated with 
appropriate medium and cells were plated at 2.5x105 
or 5x105 cells/well in triplicate in both control and 
experimental inserts. At 24 or 72 hours, cells remaining 
in the upper chamber were scraped and invaded cells were 
stained with crystal violet. Cells were counted using light 
microscopy on a 1 mm2 grid. Two 1 mm2 sections were 
counted at the edge and two at the center of each insert. 
Migration assays on laminin and fibronectin
Cells were plated in triplicate at 10,000 cells/well in 
48-well plates coated with laminin or fibronectin (Becton 
Dickson). At 48-hours post-plating, cells were imaged 
every 5 minutes for 24 hours at two points per well on 
an Olympus IX81 microscope (Olympus) with SlideBook 
4.2 software (Intelligent Imaging Innovations, Inc.). Cells 
were maintained in a humidity chamber during imaging at 
37°C and 5% CO2. Cells were tracked using the Manual 
Tracking plug-in in ImageJ [44, 45]. Average distance 
travelled and average velocity were measured for each 
line at 6, 8, 12, 16, and 24 hours.
Gelatin zymography and casein plasminogen 
zymography 
Equal amount of protein from cell-conditioned 
medium was loaded onto a 10% polyacrylamide gel 
(Sigma-Aldrich) with either 1mg/mL gelatin or 1.5 mg/mL 
casein and 0.28 units/mL plasminogen for zymography. 
After SDS-PAGE separation, gels were incubated in 
renaturing buffer (Invitrogen) to remove SDS and help the 
renaturation of proteases. The gels were then incubated 
in developing buffer (Invitrogen) at 37°C for 18 hours. 
Gels were stained with 0.25% Coomassie Blue R-250 
(Thermo Scientific) in 45% methanol, 10% acetic acid, 
and destained in methanol:water:acetic acid (2.5:6.5:1). 
No digestion was detected in control casein gels where 
plasminogen  was  omitted,  confirming  the  plasminogen 
activator nature of the uPA band.
Immunoblotting
Protein levels were measured by immunoblotting 
using antibodies specific to p110α, p85α, FAK, Phospho-
FAK (Y397), Akt, Phospho-Akt (T308), Phospho-Akt 
(S473) (Cell Signaling Technology, Danvers, MA), PTEN 
(Abcam, Cambridge, MA), and GAPDH (Santa Cruz 
Biotechnology). Whole cell lysates transferred onto PVDF 
membranes were blocked with 5% BSA prior to treatment 
with antibodies. Following secondary antibody treatment 
and thorough washing, membranes were treated with 
the SuperSignal West Pico Chemiluminescent Substrate 
(Thermo Scientific). Membranes were developed in a dark 
room using autoradiography film. 
statistical Analyses
Data were analyzed using the student’s t-test. A 
result with a p-value of less than or equal to 0.05 was 
considered significant.
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sUPPLEMENtArY VIDEOs
Videos S1-S6. Videos of SKMG26 (Video S1), 
SKMG26 - Empty pLKO.1 (Video S2), SKMG26 
-  PIK3CA shRNA (Video S3), SKMG26 – PIK3R1 
shRNA 1 (Video S4), SKMG26 – PIK3R1 shRNA 2 
(Video S5), and SKMG26 – PIK3CA + PIK3R1 shRNA 
(Video  S6)  cell  lines  tracked  on  fibronectin  using  the 
Manual Tracking plug-in in ImageJ. Individual tracks are 
provided for all trackable cells in each video. The videos, 
supplementary figures and tables can be found online at 
www.impactjournals.com/oncotarget
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